JOYSBIO HAS DEVELOPED NEW MONKEYPOX RAPID TESTS
Il sito "il Centro Tirreno.it" utilizza cookie tecnici o assimiliati e cookie di profilazione di terze parti in forma aggregata a scopi pubblicitari e per rendere più agevole la navigazione, garantire la fruizione dei servizi, se vuoi saperne di più leggi l'informativa estesa, se decidi di continuare la navigazione consideriamo che accetti il loro uso.
25
Gio, Apr

JOYSBIO HAS DEVELOPED NEW MONKEYPOX RAPID TESTS

Immediapress
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

(Adnkronos) -  JOYSBIO, one of the world's leading manufacturers of rapid test kits, has developed two new Monkeypox tests that deliver results in 15 minutes 

TIANJIN, China, Aug. 17, 2022 /PRNewswire/ -- JOYSBIO, one of the world's leading manufacturers of lateral flow rapid test kits, is proud to announce the development of

two Monkeypox tests, both of which deliver results in 15 minutes or less. JOYSBIO recently launched a Monkeypox Antigen Rapid test and a Monkeypox IgM/IgG Antibody Rapid test, both are CE-IVD marked. The antigen test tests specimens from human serum, plasma, whole blood, throat swab, saliva, or lesion exudate to determine if there are monkeypox virus antigens. The IgM/IgG Antibody test uses a few drops of blood to find the antibodies that a person's body created after the monkeypox infection. Both tests are currently in clinical evaluation in Europe and showed reliable results with infected patients.  More information is available at https://en.joysbio.com/monkeypox-rapid-test-kit/. 

"On the heels of COVID-19, another global health concern, monkeypox," said Rick Zhang, Business Development Director for JOYSBIO. "Fortunately, we have treatments for monkeypox that can reduce the painful lesions and likelihood of death. We also have a vaccine for this disease since it's been around for a very long time. Still, before patients can be treated, they need to be properly diagnosed. Monkeypox looks like many other pox diseases. Our tests will be a great tool for healthcare professionals, especially when having limited access to PCR tests." 

Monkeypox has had a historical fatality rate of 0.1% to 11% in the general population, but it is much more of a concern among children where the fatality rate can skyrocket. Knowing what one has a disease is always the first step to surviving it. With the JOYSBIO Monkeypox antigen and antibody rapid tests, getting those answers will be much faster and allow healthcare workers to protect themselves and the public better. 

"At JOYSBIO," Zhang said. "We're committed to keeping up with all infectious threats to humanity. We will continue to improve our existing tests and develop new ones as needed. The sooner one knows that they're ill, the sooner they can take proactive steps to prevent spread and take care of oneself." 

About JOYSBIO 

JOYSBIO (Tianjin) Biotechnology Co., Ltd. is an R&D-focused Chinese biotechnology company that develops, manufactures, and supplies high-quality medical in-vitro diagnostic (IVD) rapid test kits as well as revolutionary customized reagent kits to all parts of the world. JOYSBIO was founded by a team of professionals with many years of combined technical, marketing/sales, operational, and manufacturing expertise in this industry. JOYSBIO is a world-leading lateral flow test kit developer and manufacturer that supplied more than 200 million units of SARS-COV-2 rapid test kits during the COVID-19 outbreak. 

If you would like more information about this topic, please contact Rick Zhang at +86-130-7204-9899 or email at Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.

 

Ho scritto e condiviso questo articolo
Author: Red AdnkronosWebsite: http://ilcentrotirreno.it/Email: Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.